Diplomat Pharmacy (DPLO) Getting Somewhat Positive News Coverage, Accern Reports

Media stories about Diplomat Pharmacy (NYSE:DPLO) have trended somewhat positive recently, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Diplomat Pharmacy earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.2621846967188 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

NYSE DPLO opened at $21.05 on Friday. Diplomat Pharmacy has a 1-year low of $14.23 and a 1-year high of $27.78. The company has a market capitalization of $1,608.78, a P/E ratio of 25.06 and a beta of 1.32. The company has a quick ratio of 0.66, a current ratio of 0.97 and a debt-to-equity ratio of 0.70.

How to Become a New Pot Stock Millionaire

Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings data on Monday, February 26th. The company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.02. Diplomat Pharmacy had a return on equity of 8.89% and a net margin of 0.35%. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same period last year, the business posted $0.08 EPS. Diplomat Pharmacy’s quarterly revenue was up .9% on a year-over-year basis. equities research analysts expect that Diplomat Pharmacy will post 0.93 EPS for the current fiscal year.

DPLO has been the subject of several recent analyst reports. Needham & Company LLC raised their price target on Diplomat Pharmacy from $24.00 to $26.00 and gave the company a “buy” rating in a report on Monday, January 8th. Wells Fargo reissued a “market perform” rating and issued a $25.00 price target (up from $21.50) on shares of Diplomat Pharmacy in a report on Tuesday, February 27th. Mizuho set a $25.00 price target on Diplomat Pharmacy and gave the company a “hold” rating in a report on Wednesday, January 24th. Zacks Investment Research cut Diplomat Pharmacy from a “buy” rating to a “hold” rating in a report on Wednesday, February 21st. Finally, Leerink Swann set a $30.00 price target on Diplomat Pharmacy and gave the company a “buy” rating in a report on Tuesday, February 27th. Eight analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $25.38.

In related news, Director Philip R. Hagerman sold 2,150,000 shares of the firm’s stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $20.65, for a total value of $44,397,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 30.20% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Diplomat Pharmacy (DPLO) Getting Somewhat Positive News Coverage, Accern Reports” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://stocknewstimes.com/2018/04/20/diplomat-pharmacy-dplo-getting-somewhat-positive-news-coverage-accern-reports.html.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Insider Buying and Selling by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply